ZEISS Secures NMPA Approval for Advanced Ophthalmic Microscopes in China
核心洞察
ZEISS Medical Technology (搜索) received China's NMPA approval for the ARTEVO 750 and ARTEVO 850 ophthalmic microscopes, expanding surgical visualization capabilities for Chinese ophthalmologists.
The ARTEVO 750 features enhanced resolution, intelligent RGB illumination, and intraoperative OCT for routine and complex procedures including cataract surgery, vitreoretinal surgery, and MIGS.
The ARTEVO 850 offers 3D digital visualization with up to 60% depth of field optimization and Digital Color Assistant technology for improved anatomical detail visualization.
ZEISS Medical Technology (搜索) announced that China's National Medical Products Administration (NMPA) has approved the ZEISS ARTEVO 750 and ARTEVO 850 ophthalmic microscopes, bringing advanced surgical visualization technology to Chinese ophthalmologists. The approval enables surgeons across China to access high-quality optical and digital visualization for both anterior and posterior segment procedures.
"The introduction of ZEISS ARTEVO 750 and ARTEVO 850 microscopes powerfully demonstrates our commitment to ophthalmologists in China. We will leverage the power of innovation to contribute to the advancement of eye health in China and better serve Chinese surgeons and their patients," said Martin Fischer, President & CEO of ZEISS Greater China.
ARTEVO 750: Enhanced Optical Performance
The ZEISS ARTEVO 750 represents a breakthrough in ZEISS's ophthalmic surgical microscope family, making its Chinese debut at the 2025 China International Import Expo (CIIE). The system combines advanced technology with established optical expertise, enabling surgeons to fine-tune their surgical views across routine and complex procedures.
The microscope supports multiple surgical applications including cataract and vitreoretinal surgery, corneal transplantation, and minimally invasive glaucoma surgery (MIGS). Key features include enhanced resolution, elevated depth of field, intelligent RGB illumination, and intraoperative OCT capabilities, supporting seamless end-to-end workflow integration.
"The enhanced optical resolution of the ARTEVO 750 enables us to elevate our capabilities in performing delicate ophthalmic surgeries," stated Professor Chen Jili from Shanghai Jing'an District Shibei Hospital.
ARTEVO 850: Digital Visualization Innovation
The ZEISS ARTEVO 850 is a 3D-enabled digital microscope designed for multiple ophthalmology specialties, setting new standards in digital visualization. The system combines proven digital microscope benefits with customizable 3D digital visualization, functional integration, and comprehensive medical ecosystem integration.
The Digital Color Assistant (DCA) enhances colors in surgical images to accentuate anatomical details, while the Smart Depth of Field (DoF) function optimizes depth of field by up to 60% compared to the ZEISS ARTEVO 800. A redesigned user interface for ZEISS CALLISTO eye centralizes all controls onto a single intuitive touchscreen.
Digital integration capabilities allow seamless data transfer, with reference image matching directly on the 3D screen and markerless toric IOL implantation under full surgeon control.
"The resolution of the ARTEVO 850 is truly excellent, and the clear visibility and reduced fatigue during the surgery make the experience very pleasant," explained Professor Xu Gezhi from the EENT Hospital of Fudan University.
Market Impact and Future Availability
The availability of next-generation ZEISS ophthalmic microscopes in China transforms the surgical experience through superior optics and enhanced capabilities. Both systems provide end-to-end workflow integration designed to improve efficiency, precision, and surgical safety for Chinese ophthalmologists.
The ZEISS ARTEVO 850 will be showcased as part of ZEISS's ophthalmic workflows at the 41st Asia-Pacific Academy of Ophthalmology (APAO) conference in Hong Kong from February 5-8, 2026.
ZEISS Medical Technology (搜索), with 5,730 employees worldwide, generated revenue of €2,066.1 million in fiscal year 2023/24. The company maintains significant presence in rapidly developing economies through its Center for Application and Research in Bangalore, India, and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China.